Cardiotoxicity: Clinical Trials

255 trials for Cardiotoxicity, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

90 completed, 70 unknown, 43 recruiting, 21 terminated. 64 Not applicable, 34 Phase 2, 24 Phase 3, 10 Phase 1, 10 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable64Completed 21, Unknown 20, Recruiting 11, Terminated 6, Active not recruiting 3, Not yet recruiting 3
Phase 234Terminated 9, Unknown 9, Completed 8, Recruiting 6, Not yet recruiting 2
Phase 324Completed 10, Unknown 7, Recruiting 4, Active not recruiting 1, Not yet recruiting 1, Terminated 1
Phase 110Completed 5, Not yet recruiting 2, Unknown 2, Recruiting 1
Phase 410Completed 4, Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Unknown 1
Early Phase 11Terminated 1

Follow this condition Literature Review of Cardiotoxicity trials Research Report on Cardiotoxicity

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Clinical Decision Aid, Standard Care - Heart Failure, Coronary Artery Disease
Not yet recruitingMedical College of Wisconsin602026-12-012025-10-14
Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer
Phase 1Not yet recruitingWashington University School of Medicine362026-11-012026-09-24
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)
Mobile Cardiac Telemetry, Wearable Cardiac Monitor - Cardiotoxicity, Cancer
Not applicableNot yet recruitingUniversity of Minnesota722026-10-292026-10-06
Cardiac Biomarkers in Patients Receiving Immune Checkpoint Inhibitors (PRIME-ICI)
Cardiotoxicity, Cardiac Biomarkers
Not yet recruitingSouth Tees Hospitals NHS Foundation Trust3002026-10-122026-10-08
Cardioprotection Effect of Linagliptin
Doxorubicin, Empaglifloz 5 mg orally once daily - Cardiotoxicity
Phase 3Not yet recruitingTanta University1402026-10-012026-10-15
Heart Failure in Women: Epidemiological and Prognostic Insights
Heart Failure
RecruitingCarolina Ortiz Cortes4302026-09-172026-10-21
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz - Non Small Cell Lung Cancer, Cardiotoxicity
Phase 2RecruitingIndiana University102026-09-012026-09-15
The CARDIOPROTECT Trial
Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
Phase 2RecruitingBeth Israel Deaconess Medical Center602026-08-312026-07-27
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Sotagliflozin, Placebo - Anthracycline-induced Cardiotoxicity, Lymphoma
Phase 2Not yet recruitingIcahn School of Medicine at Mount Sinai602026-07-012026-05-07
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
Cardiotoxicity
RecruitingBeneficência Portuguesa de São Paulo10002026-05-112026-06-23
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
Breast Cancer (Early Breast Cancer), Cardiotoxicity
RecruitingFatih GURLER1002026-05-112026-09-16
JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
Intervention - Low Risk Group OR Intermediate Risk Group - Cardiovascular Health, Breast Cancer
Not applicableRecruitingWomen's College Hospital3002026-04-222026-06-15
Artificial Intelligence for Reconstruction of Echocardiography Studies
V-echo, L-echo - Cardiotoxicity
Not yet recruitingThe Royal Wolverhampton Hospitals NHS Trust1202026-04-012026-02-11
Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy
CMR based measurement of cardiotoxicity, biosampling for scientific research in study-specific biobank - Cardiotoxicity, Anthracycline-induced Cardiotoxicity
Not applicableRecruitingRobert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)932026-03-042026-04-14
Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial
HIIT Exercise Program, MICT Exercise Program - Childhood Cancer Survivors, Cardiotoxicity
Not applicableActive not recruitingDana-Farber Cancer Institute202026-03-042026-03-18
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
Rosuvastatin 20 mg/day, Placebo tablets similar to rosuvastatin 20mg tablets - Anthracycline-induced Cardiac Toxicity, Breast Cancer
Phase 4Not yet recruitingShiraz University of Medical Sciences4002026-02-012025-12-10
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
High efficiency particulate air filtration system (nightly administration), High efficiency particulate air filtration system (nightly and daily administration), Air filtration system without filters (sham) - Cancer Survivors, Cardiotoxicity
Not applicableCompletedUniversity College, London102026-01-232026-08-04
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Cardiotoxicity, DPP3
RecruitingAssistance Publique - Hôpitaux de Paris4002025-12-252026-09-25
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Cardiotoxicity, Heart Failure
RecruitingUniversity Hospital, Caen6002025-10-292026-03-19
Novel On-body Evaluation of Cardiac Health for Oncology
Cardiotoxicity, Heart Failure
Enrolling by invitationSkribe Medical10002025-10-092026-10-05

Showing 20 of 255. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (99)  ·  Heart Failure (44)  ·  Neoplasms (43)  ·  Lymphoma (20)  ·  Cardiovascular Diseases (15)  ·  Cardiomyopathies (10)  ·  Motor Activity (9)  ·  Heart Diseases (8)  ·  Lung Neoplasms (8)  ·  Ventricular Dysfunction, Left (8)  ·  Carcinoma, Non-Small-Cell Lung (7)  ·  Hodgkin Disease (6)  ·  Leukemia (6)  ·  Lymphoma, Non-Hodgkin (6)

Broader conditions

Pathologic Processes (255)  ·  Pathological Conditions, Signs and Symptoms (255)  ·  Wounds and Injuries (255)  ·  Chemically-Induced Disorders (254)  ·  Drug-Related Side Effects and Adverse Reactions (251)  ·  Radiation Injuries (249)  ·  Heart Diseases (247)  ·  Cardiovascular Diseases (240)  ·  Neoplasms (135)  ·  Neoplasms by Site (121)  ·  Skin Diseases (101)  ·  Skin and Connective Tissue Diseases (101)  ·  Breast Diseases (98)  ·  Neoplasms by Histologic Type (43)  ·  Hemic and Lymphatic Diseases (40)

Interventions

Doxorubicin (19)  ·  Echocardiography (18)  ·  Cyclophosphamide (10)  ·  Dexrazoxane (10)  ·  Exercise (9)  ·  Electrocardiography (8)  ·  Trastuzumab (8)  ·  Carvedilol (7)  ·  Razoxane (6)  ·  Vincristine (5)  ·  Atorvastatin (4)  ·  Docetaxel (4)  ·  Filgrastim (4)  ·  Radiotherapy (4)  ·  Anthracyclines (3)

Sponsors

Abramson Cancer Center at Penn Medicine (10)  ·  Children's Oncology Group (5)  ·  Groupe Hospitalier Pitie-Salpetriere (5)  ·  University College, London (5)  ·  Ain Shams University (4)  ·  Assistance Publique - Hôpitaux de Paris (4)  ·  Peking University Third Hospital (4)  ·  Washington University School of Medicine (4)  ·  AHS Cancer Control Alberta (3)  ·  Istanbul University (3)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  National Cancer Institute (NCI) (3)  ·  Radboud University Medical Center (3)  ·  Tanta University (3)  ·  University Health Network, Toronto (3)

Countries

United States (68)  ·  Canada (24)  ·  France (21)  ·  China (16)  ·  United Kingdom (15)  ·  Italy (13)  ·  Netherlands (12)  ·  Egypt (11)  ·  Spain (9)  ·  Brazil (7)  ·  Germany (6)  ·  Poland (6)  ·  Switzerland (6)  ·  Turkey (Türkiye) (6)  ·  Australia (5)

Top investigators

Bonnie Ky, MD, MSCE (6)  ·  Cafer Zorkun, MD PhD (3)  ·  Marielle Scherrer-Crosbie, MD, PhD (3)  ·  Anthony Yu, MD (2)  ·  Cindy Schwartz, MD (2)  ·  Laurence J. van Warmerdam, MD, PhD (2)  ·  Zhi Yang, PhD (2)  ·  A. van Rhenen, MD (1)  ·  Ahmed L Mohamed, Master (1)  ·  Alison Macklin (1)  ·  Alister Hart, MD,FRCSG (1)  ·  Allan Kluser Sales, PhD (1)  ·  Andrea Natale, MD (1)

Results publications

PMID 36207229, PMID 10761937, PMID 11263649, PMID 11913479, PMID 12948221, PMID 13211322, PMID 14349898, PMID 15473335, PMID 15477280, PMID 16131888, PMID 16332601, PMID 16568436, PMID 17068719, PMID 18757952, PMID 18827237, PMID 18835128, PMID 19257889, PMID 19304018, PMID 19483225, PMID 19584400, PMID 19794161, PMID 19937124, PMID 20544916, PMID 20859129, PMID 21037026, PMID 21656317, PMID 21692725, PMID 21794114, PMID 21969427, PMID 22252702, PMID 22308623, PMID 22336970, PMID 22351785, PMID 22374741, PMID 22419548, PMID 22447496, PMID 22455358, PMID 22520206, PMID 22689804, PMID 22723536, PMID 22911615, PMID 23090916, PMID 23273589, PMID 23307670, PMID 23313008, PMID 23421810, PMID 23762480, PMID 23813157, PMID 23948123, PMID 24103764

NIH funding

2009 (1), 2019 (1), 2023 (1), P30CA012197 (1), P30CA015083 (1), P30CA036727 (1), P30CA068485 (1), R01CA167821 (1), R01HL180913 (1), R21CA226960 (1), R21HL150723 (1), R21HL152148 (1), U01CA097452 (1), U10CA030969 (1), U10CA031946 (1)